Akeso Doses First Patient in Phase III Trial of Ivonescimab for Limited-Stage Small Cell Lung Cancer

Akeso, Inc.announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating...

August 11, 2025 | Monday | News
Junshi Biosciences’ sNDA for Toripalimab Plus Disitamab Vedotin in HER2-Expressing Urothelial Carcinoma Accepted by China’s NMPA

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...

August 11, 2025 | Monday | News
Exact Sciences Secures Exclusive U.S. Rights to Freenome’s Blood-Based Colorectal Cancer Screening Tests

Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome sub...

August 07, 2025 | Thursday | News
Janux Therapeutics Achieves $10 Million Milestone as First Patient Dosed in Merck Collaboration Trial

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (Nasdaq: JANX...

August 06, 2025 | Wednesday | News
Shilpa Medicare Backs Alveolus Bio to Accelerate Inhaled Microbiome Therapeutics for Lung Disease

- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has anno...

August 04, 2025 | Monday | News
Akeso Doses First Patient in Pivotal Phase III Trial of Ivonescimab for IO-Resistant NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMO...

July 31, 2025 | Thursday | News
Revna Biosciences and AstraZeneca Transform Lung Cancer Care in Ghana with Precision Therapy Rollout

The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial...

July 31, 2025 | Thursday | News
BriaCell and BriaPro Unveil TILsRx Platform to Advance Next-Generation Multivalent Immunotherapies for Cancer

BriaCell Therapeutics Corp. a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned s...

July 30, 2025 | Wednesday | News
Candel Therapeutics Secures EMA Orphan Designation for CAN-2409 in Pancreatic Cancer

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological ...

July 28, 2025 | Monday | News
Sanofi Secures EU Approval for Sarclisa + VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma

Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and pro...

July 28, 2025 | Monday | News
QIAGEN Launches QIAseq xHYB Long Read Panels to Enhance Targeted Genomic Analysis

Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NG...

July 23, 2025 | Wednesday | News
Rakovina Therapeutics Advances AI-Driven ATR Inhibitors in Fight Against Cancer

Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next...

July 23, 2025 | Wednesday | News
Sanofi Completes Acquisition of Blueprint Medicines, Strengthening Rare Immunology Portfolio

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a p...

July 21, 2025 | Monday | News
Johnson & Johnson’s TAR-200 Receives FDA Priority Review for BCG-Unresponsive Bladder Cancer

New Drug Application supported by results from the Phase 2b SunRISe-1 study Johnson & Johnson announced that the U.S. Food and Drug Administration (...

July 18, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close